ES2089511T3 - Dihidroquinolina antagonistas de nmda. - Google Patents

Dihidroquinolina antagonistas de nmda.

Info

Publication number
ES2089511T3
ES2089511T3 ES92907466T ES92907466T ES2089511T3 ES 2089511 T3 ES2089511 T3 ES 2089511T3 ES 92907466 T ES92907466 T ES 92907466T ES 92907466 T ES92907466 T ES 92907466T ES 2089511 T3 ES2089511 T3 ES 2089511T3
Authority
ES
Spain
Prior art keywords
nmda
antagonists
dihydrokinoline
sulfanimide
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907466T
Other languages
English (en)
Inventor
Boyd L Harrison
Bruce M Baron
David M Stemerick
Ian A Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2089511T3 publication Critical patent/ES2089511T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

EL PRESENTE INVENTO ESTA DIRIGIDO A UNA NUEVA CLASE DE DERIVADOS DE QUINOLINA SULFANOIMIDA ONISTAS DE NMDA.
ES92907466T 1991-02-27 1992-02-11 Dihidroquinolina antagonistas de nmda. Expired - Lifetime ES2089511T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66178091A 1991-02-27 1991-02-27
US70000491A 1991-05-14 1991-05-14

Publications (1)

Publication Number Publication Date
ES2089511T3 true ES2089511T3 (es) 1996-10-01

Family

ID=27098383

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907466T Expired - Lifetime ES2089511T3 (es) 1991-02-27 1992-02-11 Dihidroquinolina antagonistas de nmda.

Country Status (14)

Country Link
EP (1) EP0573562B1 (es)
JP (1) JP3465794B2 (es)
KR (1) KR100224045B1 (es)
AT (1) ATE137225T1 (es)
AU (1) AU660969B2 (es)
CA (1) CA2104297C (es)
DE (1) DE69210229T2 (es)
DK (1) DK0573562T3 (es)
ES (1) ES2089511T3 (es)
FI (1) FI103202B1 (es)
GR (1) GR3019772T3 (es)
HU (1) HU217425B (es)
NO (1) NO180485C (es)
WO (1) WO1992015565A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
WO1995014670A1 (en) * 1993-11-29 1995-06-01 Merrell Pharmaceuticals Inc. Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action
ATE177083T1 (de) * 1993-11-29 1999-03-15 Merrell Pharma Inc Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
ZA903588B (en) * 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists

Also Published As

Publication number Publication date
FI103202B (fi) 1999-05-14
FI103202B1 (fi) 1999-05-14
DE69210229D1 (de) 1996-05-30
AU1532092A (en) 1992-10-06
EP0573562A1 (en) 1993-12-15
KR100224045B1 (ko) 1999-10-15
HU217425B (hu) 2000-01-28
DE69210229T2 (de) 1996-11-14
DK0573562T3 (da) 1996-05-13
WO1992015565A1 (en) 1992-09-17
HU9302433D0 (en) 1993-11-29
CA2104297A1 (en) 1992-08-28
GR3019772T3 (en) 1996-07-31
NO180485C (no) 1997-04-30
NO933042D0 (no) 1993-08-26
NO180485B (no) 1997-01-20
JP3465794B2 (ja) 2003-11-10
FI933762A (fi) 1993-08-26
NO933042L (no) 1993-08-26
AU660969B2 (en) 1995-07-13
FI933762A0 (fi) 1993-08-26
ATE137225T1 (de) 1996-05-15
KR930703257A (ko) 1993-11-29
EP0573562B1 (en) 1996-04-24
HUT67301A (en) 1995-03-28
JPH06505746A (ja) 1994-06-30
CA2104297C (en) 2003-05-27

Similar Documents

Publication Publication Date Title
PT641343E (pt) Derivados de 4-mercaptoacetilamino-¬2|benzazapinona (3) e a sua utilizacao como inibidores de encefalinase
EP0539503A4 (es)
ES2072607T3 (es) Derivados 3 indolil tioacetato.
DE69230224D1 (de) Potenzierung von nmda-antagonisten
ES2089511T3 (es) Dihidroquinolina antagonistas de nmda.
DK0532629T3 (da) 1-Piperidinyl-alkanoylarylsulfonamid-derivater
ATE131172T1 (de) Heterocyclische nmda antagonisten.
DK0535713T3 (da) Anvendelse af 2-carbomethoxy-1-pyrrolin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573562

Country of ref document: ES

FG2A Definitive protection

Ref document number: 573562

Country of ref document: ES